Peanut (Arachis hypogaea) Allergen Powder-dnfp

The European Commission has approved Palforzia for treating peanut allergies in toddlers aged 1-3, expanding its availability in Europe.

The European Medicines Agency's CHMP has recommended Palforzia for treating peanut allergies in toddlers aged 1-3, marking a potential expansion of its use.

IgGenix has dosed the first patient in its Phase 1 ACCELERATE Peanut trial, evaluating IGNX001, a novel monoclonal antibody for peanut allergy.

Lurie Children's Hospital is conducting clinical trials for peanut allergies, focusing on reducing the risk of severe reactions from accidental exposure.

The FDA has expanded the approval of Palforzia to include children aged 1 through 3 years with a confirmed peanut allergy.